EyeGate Pharmaceuticals Inc expected to post a loss of 42 cents a share - Earnings Preview

Kiora Pharmaceuticals

06/08/2021 03:53

* EyeGate Pharmaceuticals Inc  EYEG.OQ   EYEG.O  is expected
to show a no change in quarterly revenue when it reports
results on August 5 (estimated). 
​* Refinitiv's mean analyst estimate for EyeGate Pharmaceuticals
Inc is for a loss of 42 cents per share. For the same quarter
last year, the company reported a loss of 38 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for EyeGate
Pharmaceuticals Inc is $14​, about 83% above​ its last closing
price of $2.38. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.39       -0.38      -0.37     Beat    3.9
 Dec. 31 2020  -0.44       -0.44      -0.52     Missed  -18.2
 Sep. 30 2020  -0.42       -0.42      -0.44     Missed  -4.8​
 Jun. 30 2020  -0.43       -0.43      -0.38     Beat    11.6
 ​​            ​                                        ​
 Dec. 31 2019  -0.81       -0.81      -0.71     Beat    11.7​
 Jun. 30 2019  -0.75       -0.75      -0.60     Beat    20
 This summary was machine generated August 6 at 02:53 GMT.  All
figures in US dollars unless otherwise stated